Sex differences in ACE2, TMPRSS2, and HLA-DQA2 expression in gray matter: Implications for post-COVID-19 neurological symptoms

Publication date: Nov 03, 2024

COVID-19 has been associated with sex differences in terms of mortality and morbidity. Viral entry proteins including those regulated by ACE2 and TMPRSS2 may play a role, but few studies have been conducted to date and none have examined sex differences in brain expression. Additionally, HLA-DQA2 expression has emerged as a potential moderator of COVID-19 outcomes. Using non-invasive imaging transcriptomics, we measured ACE2, TMPRSS2, and HLA-DQA2 mRNA expression in gray matter volumes using MRI scans obtained from 1,045 healthy adults aged 21-35 years (44% male) imaged prior to the COVID-19 pandemic. ACE2 (t = 9.24, p < 0.001, d = 0.576), TMPRSS2 (t = 24.66, p < 0.001, d = 1.54), and HLA-DQA2 (t = 3.70, p < 0.001, d = 0.231) expression was significantly higher in males compared to females. Bayesian network analysis indicated significant (p < 0.05) positive causal paths from ACE2 to HLA-DQA2 (B = 0.282), ACE2 to TMPRSS2 (B = 0.357), and TMPRSS2 to HLA-DQA1 (B = 0.139) and a negative causal path from sex (males = -1, females = 1) to TMPRSS2 (B = -0.607). Our results have important implications for neurological symptoms associated with COVID-19 and long COVID including complex interactions between viral entry proteins and immune responses, sex-related disparities in symptom reporting and diagnosis, assessment of neurological problems after COVID-19, and potential COVID-19 related syndemics. However, further research is needed to determine gene expression patterns by sex and COVID-19 outcomes, to evaluate additional genes that may influence neurologic status, and studies that include objective assessments of neurologic outcomes.

PDF

Concepts Keywords
Mayordomo Ace2
Neuroscience Al
Texas Brain
Urinary Covid
Differences
Dqa2
Expression
Gray
Hla
International
Matter
Medrxiv
Preprint
Sex
Symptoms

Semantics

Type Source Name
disease MESH COVID-19
disease MESH morbidity
disease IDO role
disease MESH long COVID
disease IDO symptom
disease IDO host
disease MESH infection
disease MESH histocompatibility
disease MESH emergency
disease MESH Sequelae
disease MESH cognitive dysfunction
disease MESH brain fog
disease MESH neurologic symptoms
disease MESH neuroinflammation
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH multiple sclerosis
disease MESH Alzheimer’s disease
pathway REACTOME Release
disease MESH Privacy
drug DRUGBANK Flunarizine
disease MESH inflammation
disease IDO immune response
disease MESH depression
disease MESH anxiety
drug DRUGBANK Isoxaflutole
disease MESH cytokine storm
disease MESH Causes
disease IDO cell
disease IDO humoral immune response
disease MESH Syndrome
disease MESH demyelination
disease MESH Dementias
disease MESH Brain Disorders
disease MESH respiratory diseases
disease MESH autoimmune disease
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Cyclic Adenosine Monophosphate
disease MESH abnormalities
disease MESH Neurocognitive Disorders

Download Document

(Visited 3 times, 1 visits today)